Fouad Namouni, M.D., is Head of Oncology Development at Bristol-Myers Squibb (BMS). In this position, he has responsibility for ensuring the safe and appropriate use of the company's products and for creating a comprehensive portfolio strategy for Oncology and driving product development plans from the early stage of clinical development through commercialization. He is accountable to Tom Lynch, Chief Scientific Officer, and is a member of the R&D Executive Leadership Team and the Commercial Leadership Team. Before taking on his current role, Fouad was Head of Development for Opdivo(r) and Yervoy(r). Under his leadership, Opdivo received approval for the treatment of metastatic squamous non-small cell lung cancer (NSCLC) and unresectable or metastatic melanoma, as well as expanded approval in previously treated NSCLC in the United States and European markets. He received his medical degree from the University of Annaba Medical School in Algeria, and Pediatrics degree from Université Rene Descartes in Paris, France. He also received his Pediatric Oncology and Hematology degree and a M.S. in clinical and experimental pharmacology from Université Paris-Sud in France.